EU antitrust regulators are set to fine generic drugmaker Teva in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone, Reuters reports, citing people with direct knowledge of the matter. The move will come after the European Commission charged the Israeli company two years ago for breaching EU antitrust rules, the report noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- EU set to fine Teva for disparaging rival to Copaxone, Reuters reports
- Teva case for multiple expansion ‘remains solid,’ says Jefferies
- Teva provides update on Olanzapine LAI trial
- Teva price target raised to $26 from $24 at UBS
- Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference